Skip to content
Homepage
Author:
Unicycive Therapeutics, Inc.
Posted Date:
August 12, 2026
Unicycive Therapeutics Announces Second Quarter 2026 Financial Results and Provides Business Update
Unicycive Therapeutics, Inc.
August 12, 2026
Unicycive Therapeutics Receives Complete Response Letter from FDA Regarding Resubmitted Oxylanthanum Carbonate (OLC) New Drug Application (NDA)
Unicycive Therapeutics, Inc.
June 30, 2026
